How MEDVi Works: The Telehealth Business Model Behind the Two-Person GLP-1 Brand

Checked October 18, 2026, from MEDVi's own pages, FDA and court records, and reputable press. Figures about revenue and customers are company-reported.

What MEDVi sells

MEDVi, LLC describes itself in its terms as a Delaware company (MEDVi terms). On October 18, 2026 its site offered (MEDVi):

• Weight loss: compounded GLP-1 injections and daily dissolvable tablets, plus branded Wegovy (injection and pill) and Zepbound for a "$99 Membership + Medication Cost."
• Men's health: "QUAD by MEDVi," a compounded sublingual liquid for erectile dysfunction (MEDVi), which the New York Times reported reached 50,000 customers in its first month after a February 2026 launch.
• Meals: a chef-made meal delivery add-on.
• Coming soon: women's health, peptides and longevity, supplements, hair and skin.

The site states that compounded GLP-1s "are not FDA-approved or evaluated for safety, efficacy, or quality." It doesn't publish the states it serves; its terms say to ask customer service.

The offer

Multi-month bundles bring the monthly price down, and promotions vary what a visitor sees. The structure (a discounted first month, a higher ongoing price and prepaid bundles) is the standard GLP-1 offer. Cancellation must come at least 72 hours before the next billing date, with no refund for the month already billed (refund policy).

The stack behind it

MEDVi discloses its partners in the footer of every page:

• Medical groups: "Medical treatment is provided by 'CareGLP Affiliated P.C.s,' and OpenLoop Health," and OpenLoop clinicians "retain the decision to prescribe."
• Pharmacies: Triad Rx (Daphne, Alabama), RedRock Pharmacy (St. George, Utah) and Beaker Pharmacy & Compounding (McKinney, Texas).
• Payments: Stripe and/or QuickBooks (privacy policy).

The New York Times reported that CareValidate supplies telehealth software, doctors and prescription fulfilment, and that OpenLoop handles doctors, pharmacies, shipping and compliance. CareValidate shows MEDVi among the brand logos on its homepage (CareValidate). In other words: MEDVi doesn't employ clinicians, run a pharmacy or build medical software. It rents all three from white-label partners, the model compared in our guide to telehealth infrastructure partners.

Using two clinical vendors gives a brand redundancy and pricing leverage. It also means each vendor's problems become the brand's problems: OpenLoop's January 2026 data breach and a November 2025 lawsuit against OpenLoop and Triad Rx over compounded oral tirzepatide both involved MEDVi customers (Fierce Healthcare). MEDVi wasn't a defendant.

How it grew

The New York Times profile on April 2, 2026 reported (NYT):

• MEDVi opened in September 2024, built in about two months for about $20,000, much of it with AI tools for code, copy, ad images and video, and customer service.
• $401 million in 2025 sales at a 16.2% net margin, about 250,000 customers by the end of 2025, and a pace of $1.8 billion for 2026. The founder and one other employee run it, with contractors and outside firms.
• No outside funding.

Those numbers are company-reported, although the Times said it reviewed the financials. MEDVi's site now claims "500,000+ patients."

Acquisition is paid social and affiliates. Business Insider reported more than 5,000 active Meta ads under the MEDVi name in early April 2026. It said many ran under physician personas that "don't appear to exist," and the count fell to about 2,800 after it asked about them (Drug Discovery & Development summary). The founder told Business Insider that "maybe 30%" of advertising ran through affiliates. MEDVi's own terms acknowledge visitors may arrive through sites "operated or controlled by a third party, including by an affiliate."

The FDA letter and the backlash

FDA warning letter, February 20, 2026. FDA wrote to "MEDVi, LLC dba MEDVi" about its medvi.io website (FDA). It cited:

• "Same active ingredient as Wegovy® and Ozempic®" and "Same active ingredient as Mounjaro® and Zepbound®," claims FDA said imply the compounded products are FDA-approved;
• product images labelled "MEDVi," "suggesting MEDVi is the compounder of those drugs when in fact it is not."

Those are the two most-cited patterns in FDA's 2025–2026 telehealth letters (our 503A vs 503B guide). MEDVi said publicly in April that medvi.io belonged to an affiliate agency. Trade press disputed that, pointing to the address and branding on the site (Drug Discovery & Development).

The April 2026 spike. US searches for "medvi" peaked at about 201,000 that month. The Times story went viral on April 2. Within a week, Business Insider, Futurism, Techdirt and others published critical follow-ups on the ads, the FDA letter and AI-generated imagery (Futurism). The Times itself had reported that early site images included AI-generated models and altered before-and-after photos.

Lawsuits. A 2025 Telephone Consumer Protection Act case in Florida was voluntarily dismissed (docket). A proposed class action filed in California in March 2026 alleges spam emails sent by affiliates, as reported by Drug Discovery & Development; those are allegations, not findings. We found no FTC or state action against MEDVi.

What to copy, and what not to

Worth copying:

• Rent the clinical layer. A white-label clinician network plus 503A pharmacies lets a brand serve patients nationally without hiring clinicians or building a medical group. See friendly PC and MSO structures.
• Keep a second vendor. Two clinical partners protect you from one partner's outage, breach or pricing change.
• Test the offer constantly. Intake quizzes, first-month pricing and bundles are where conversion is won.
• Expand to your existing customers. MEDVi's ED and meal launches went to an audience it already had.

Don't copy:

• "Same active ingredient as Wegovy" claims, or vials branded as if you compound them. FDA cited exactly these.
• Ads with personas, AI "doctors" or altered before-and-after photos. They became the story, and they put ad accounts and LegitScript status at risk (our LegitScript guide).
• Affiliates you don't control. The brand is the one that gets the warning letter and the lawsuit. Approve affiliate copy, track it, and cut off anyone who goes off-script.
• Outcome claims you can't support, such as an average weight loss for a compounded product. The FTC requires competent and reliable scientific evidence (FTC).

The takeaway: the model is real. A small team can build a large telehealth business on rented infrastructure, and the economics are attractive (model your own in the profit calculator). But at this scale every shortcut in claims, ads and affiliates becomes visible, and the rules for compounded drugs are tightening. Build the compliance in from the first ad.

---